Myriad Ruling: Just BRCA Genes or Underpinnings of Biotech?
By Donna Young
Wednesday, March 31, 2010
If upheld on appeal, a federal district judge's ruling Monday that invalidated patent claims related to the BRCA1 and BRCA2 genes held by Salt Lake City-based Myriad Genetics Inc. and the University of Utah Research Foundation could have far-reaching implications for gene patenting and the future of biotechnology product development. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.